When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson’s disease?

Silvio R. De Luka; Marina Svetel; Tatjana Pekmezović; Branislav Milovanovic; Vladimir S. Kostic

doi:10.2298/2150

Silvio R. De Luka Institute of Pathological Physiology, Clinical Center of Serbia
Marina Svetel Institute of Neurology, Clinical Center of Serbia
Tatjana Pekmezović Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Branislav Milovanovic Clinical Hospital Center “Bežanijska Kosa”, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Vladimir S. Kostic Institute of Neurology, Clinical Center of Serbia

DOI: https://doi.org/10.2298/2150

Keywords: parkinson disease, autonomic nervous system,

Abstract

Background/Aim. Dysautonomia appears in almost all patients with Parkinson’s disease (PD) in a certain stage of their condition. The aim of our study was to detect the development and type of autonomic disorders, find out the factors affecting their manifestation by analyzing the potential association with demographic variables related to clinical presentation, as well as the symptoms of the disease in a PD patient cohort. Methods. The patients with PD treated at the Clinic of Neurology in Belgrade during a 2-year period, divided into 3 groups were studied: 25 de novo patients, 25 patients already treated and had no long-term levodopa therapy-related complications and 22 patients treated with levodopa who manifested levodopa-induced motor complications. Simultaneously, 35 healthy control subjects, matched by age and sex, were also analyzed. Results. Autonomic nervous system malfunction was defined by Ewing diagnostic criteria. The tests, indicators of sympathetic and parasympathetic nervous systems, were significantly different in the PD patients as compared with the controls, suggesting the failure of both systems. However, it was shown, in the selected groups of patients, that the malfunction of both systems was present in two treated groups of PD patients, while de novo group manifested only sympathetic dysfunction. For this reason, the complete autonomic neuropathy was diagnosed only in the treated PD patients, while de novo patients were defined as those with the isolated sympathetic dysfunction. The patients with the complete autonomic neuropathy differed from the subjects without such neuropathy in higher cumulative and motor unified Parkinson’s disease rating score (UPDRS) (p < 0.01), activities of daily living scores (p < 0.05), Schwab-England scale (p < 0.001) and Hoehn-Yahr scale. There was no difference between the patients in other clinical-demographic characteristics (sex, age at the time of diagnosis, actual age, duration of disease, involved side of the body, pain and freezing), but mini mental status (MMS) score and Hamilton depression and anxiety rating scale were significantly lower (p < 0.05). Conclusion. Our results confirm a high prevalence of autonomic nervous system disturbances among PD patients from the near onset of disease, with a predominant sympathetic nervous system involvement. The patients who developed complete autonomic neuropathy (both sympathetic and parasympathetic) were individuals with considerable level of functional failure, more severe clinical presentation and the existing anxiety and depression.

References

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinsonism – a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55(3): 181−4.

Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish defi-nite multiple system atrophy from Parkinson’s disease? J Neu-rol Neurosurg Psychiatry 2000; 68(4): 434−40.

Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of or-thostatic hypotension in a community based cohort of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75(10):1470−1.

Kummer A, Teixeira AL. Neuropsychiatry of Parkinson’s dis-ease. Arq Neuropsiquiatr 2009; 67(3B): 930−9.

Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitabil-ity of dementia at 20 years. Mov Disord 2008; 23(6): 837−44.

Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Auton Res 2007; 17(2): 118−21.

Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D. The pa-tients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Mov Disord 2011; 26(4): 653−8.

Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24(2): 197−211.

Ewing DJ. Recent advances in the non-invasive investigation of diabetic autonomic neuropathy. In: Bannister R, editor. Auto-nomic failure – a textbook of clinical disorders of autonomic nervous system. 2nd ed. Oxford: Oxford University Press; 1988.

Folstein MF, Folstein SE, McHugh PR. “Mini Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189−98.

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56−62.

Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32(1): 50–5.

Zakrzewska-Pniewska B, Jamrozik Z. Are electrophysiological au-tonomic tests useful in the assessment of dysautonomia in Parkinson’s disease? Parkinsonism Relat Disord 2003; 9(3): 179−83.

Fischer M, Gemende I, Marsch WC, Fischer PA. Skin function and skin disorders in Parkinson’s disease. J Neural Transm 2001; 108(2): 205−13.

Dewey RB Jr. Autonomic dysfunction in Parkinson’s disease. Neurol Clin. 2004; 22(3 Suppl): S127−39.

Shibata M, Morita Y, Shimizu T, Takahashi K, Suzuki N. Cardiac parasympathetic dysfunction concurrent with cardiac sympa-thetic denervation in Parkinson’s disease. J Neurol Sci 2009; 276(1−2): 79−83.

Buob A, Winter H, Kindermann M, Becker G, Möller JC, Oertel WH, et al. Parasympathetic but not sympathetic cardiac dysfunction at early stages of Parkinson's disease. Clin Res Cardiol 2010; 99(11): 701−6.

Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabaya-shi K, et al. Axonal ά-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s dis-ease. Brain 2008; 131(Pt 3): 642−50.

Okada Y, Ito Y, Aida J, Yasuhara M, Ohkawa S, Hirokawa K. Lewy bodies in the sinoatrial nodal ganglion: clinicopathologi-cal studies. Pathol Int 2004; 54(Pt 3): 682−7.

Barbic F, Perego F, Canesi M, Gianni M, Biagiotti S, Costatino G, et al. Early abnormalities of vascular and cardiac autonomic con-trol in Parkinson’s disease without orthostatic hypotension. Hypertension 2007; 49(1): 120-126.

Mihci E, Kardelen F, Dora B, Balkan S. Orthostatic heart rate va-riability analysis in idiopathic Parkinson’s disease. Acta Neurol Scand 2006; 113(5): 288−93.

Druschky A, Hilz MJ, Platsch G Radespiel-Tröger M, Druschky K, Kuwert T, et al. Differentiation of Parkinson’s disease and mul-tiple system atrophy in early disease stages by means of I-123-MIBG-spect. J Neurol Sci. 2000; 175(1): 3−12.

Goldstein DS, Holmes C, Sewell L, Park MY, Sharabi Y. Sympa-thetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy. Clin Auton Res. 2011; 22(1): 57−61.

Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001; 57(3): 456−62.

Langston JW. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59(4): 591−6.

Miyamoto T, Miyamoto M, Iwanami M, Hirata K. Cardiac 123I-MIBG accumulation in Parkinson’s disease differs in associa-tion with REM sleep behaviour disorder. Parkinsonism Relat Disord 2011; 17(3): 219−20.

Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson’s disease: a comprehensive symp-tom survey. Parkinsonism Relat Disord 2002; 8(4): 277−84.

Riley DE, Chelimsky TC. Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003; 74(1): 56−60.

Bouhaddi M, Vuillier F, Fortat JO, Capelle S, Henriet MT, Rumbach L, et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s disease: in-volvement of L-dopa therapy. Auton Neurosci 2004; 116(1−2): 30−8.

Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkin-son’s disease. Neurology 2007; 69(4): 333−41.

Blackett H, Walker R, Wood B. Urinary dysfunction in Parkin-son’s disease: a review. Parkinsonism Relat Disord 2009; 15(2): 81−7.

Mathias C. Autonomic disorders and their recognition. N Engl J Med 1997; 336(10): 721−4.

Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci 2001; 92(1−2): 76−85.

Lucetti C, Gambaccini G, Del Dotto P, Ceravolo R, Logi C, Rossi G, et al. Long-term clinical evaluation in patients with Parkinson’s disease and early autonomic involvement. Parkinsonism Relat Disord. 2006; 12(5): 279−83.